RxDoctor Payments Data

Joseph Gutman, MD

Endocrinology, Diabetes & Metabolism · Plantation, FLNPI 1780633875

Payments from drug & device makers

$4,357in general payments, 2019–2025

Across 42 payments — averaging $103.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$4K
  • Lundbeck LLC$95
  • Boston Scientific$92
  • Insulet Corporation$50
  • Merck$49
  • Abbott$45
  • plus $382 from 15 others

What the payments were for

  • Consulting fees$3,40078%
  • Food & beverage$94122%
  • Education$170%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,357 in reported general payments places this provider in the 50th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida

Medicare billing

Part B allowed, 2024
$86,341
Medicare patients
322
Services billed
1,927

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin95$100,707
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog58$66,340
MounjaroTirzepatide58$58,838
TrulicityDulaglutide54$58,631
OzempicSemaglutide41$57,520
Tresiba Flextouch U-100Insulin Degludec80$50,061
FarxigaDapagliflozin Propanediol30$43,604
Tresiba Flextouch U-200Insulin Degludec15$26,009
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog29$23,346
EliquisApixaban18$20,547
Lantus SolostarInsulin Glargine,hum.Rec.Anlog110$16,401
JanuviaSitagliptin Phosphate16$12,142
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$11,647
Cinacalcet Hcl20$9,966
HumalogInsulin Lispro30$9,290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$31$126,759142 claims
Boehringer IngelheimJardiance$38$100,70795 claims
Novo NordiskOzempic$3,644$57,52041 claims
AstraZenecaFarxiga$20$43,60430 claims
PfizerEliquis$18$20,54718 claims
MerckJanuvia$49$12,14216 claims
AbbVieSynthroid$29$1,25720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

Other endocrinology, diabetes & metabolism in Plantation

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →